Histone methyltransferase hSETD1A is a novel regulator of metastasis in breast cancer

Molecular Cancer Research

Volumn 13, Issue 3, 2015, Pages 461-469

  Salz, Tal ^a   Deng, Changwang ^a   Pampo, Christine ^a   Siemann, Dietmar ^a,b   Qiu, Yi ^a,b   Brown, Kevin ^a,b   Huang, Suming ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; HISTONE H3; HISTONE METHYLTRANSFERASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE 17; SETD1A ENZYME; STROMELYSIN 3; UNCLASSIFIED DRUG; HISTONE; HISTONE LYSINE METHYLTRANSFERASE; MATRIX METALLOPROTEINASE; SETD1A PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; ANIMAL; BREAST TUMOR; CELL MOTION; GENETIC EPIGENESIS; GENETICS; MCF 7 CELL LINE; METABOLISM; METHYLATION; PATHOLOGY; TUMOR CELL LINE;

MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPIGENESIS, GENETIC; FEMALE; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; MATRIX METALLOPROTEINASES; MCF-7 CELLS; METHYLATION; MICE; NEOPLASM METASTASIS; UP-REGULATION;

EID: 84928040738     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-14-0389     Document Type: Article

References (64)

1. Breast cancer facts and figures 2013-2014. Atlanta, GA: American Cancer Society; 2013.
2. Liu Y, Liu K, Qin S, Xu C, Min J. Epigenetic targets and drug discovery. Part 1: histone methylation. Pharmacol Ther 2014;143:275-94.
3. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011;17:330-9.
4. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 2013; 13:497-510.
5. Feinberg AP. The epigenetic basis of common human disease. Trans Am Clin Climatol Assoc 2013;124:84-93.
6. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12-27.
7. Pujadas E, Feinberg AP. Regulated noise in the epigenetic landscape of development and disease. Cell 2012;148:1123-31.
8. Mair B, Kubicek S, Nijman SM. Exploiting epigenetic vulnerabilities for cancer therapeutics. Trends Pharmacol Sci 2014;35:136-45.
9. Yoo KH, Hennighausen L. EZH2 methyltransferase and H3K27 methylation in breast cancer. Int J Biol Sci 2012;8:59-65.
10. Alford SH, Toy K, Merajver SD, Kleer CG. Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression. Breast Cancer Res Treat 2012;132:429-37.
11. Pang J, Toy KA, Griffith KA, Awuah B, Quayson S, Newman LA, et al. Invasive breast carcinomas in Ghana: high frequency of high grade, basallike histology and high EZH2 expression. Breast Cancer Res Treat 2012; 135:59-66.
12. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, et al. Lysinespecific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010;31:512-20.
13. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962-8.
14. Kim JH, Sharma A, Dhar SS, Lee SH, Gu B, Chan CH, et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 2014;74:1705-17.
15. Berdel B, Nieminen K, Soini Y, Tengstrom M, Malinen M, Kosma VM, et al. Histone demethylase GASC1-a potential prognostic and predictivemarker in invasive breast cancer. BMC Cancer 2012;12:516.
16. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. Highresolution profiling of histone methylations in the human genome. Cell 2007;129:823-37.
17. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, et al. Genomic maps and comparative analysis of histonemodifications in human and mouse. Cell 2005;120:169-81.
18. Heintzman ND, Stuart RK, Hon G, Fu Y, Ching CW, Hawkins RD, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007;39:311-8.
19. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA, et al. A high-resolution map of active promoters in the human genome. Nature 2005;436:876-80.
20. Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, et al. Epigenomic enhancer profiling defines a signature of colon cancer. Science 2012;336:736-9.
21. Ellinger J, Kahl P, Mertens C, Rogenhofer S, Hauser S, Hartmann W, et al. Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer 2010;127:2360-6.
22. Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I, et al. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010;70:61-9.
23. He C, Xu J, Zhang J, Xie D, Ye H, Xiao Z, et al. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum Pathol 2012;43:1425-35.
24. Ke XS, Qu Y, Rostad K, Li WC, Lin B, Halvorsen OJ, et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS ONE 2009;4: e4687.
25. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011;18:867-74.
26. Salz T, Li G, Kaye FJ, Zhou L, Qiu Y, Huang S. hSETD1A regulates Wnt target genes and controls tumor growth of colorectal cancer cells. Cancer Res 2014;74:775-86.
27. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem 2012;81:65-95.
28. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941-53.
29. Secombe J, Li L, Carlos L, Eisenman RN. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev 2007;21:537-51.
30. Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F, et al. The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 2007;447:601-5.
31. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, et al. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007;25:801-12.
32. Lee MG, Norman J, Shilatifard A, Shiekhattar R. Physical and functional association of a trimethyl H3K4 demethylase and Ring6a/MBLR, a polycomb- like protein. Cell 2007;128:877-87.
33. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
34. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013;342:1234850.
35. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
36. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
37. Li Q, Shi L, Gui B, Yu W, Wang J, Zhang D, et al. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis andmetastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res 2011;71:6899-908.
38. Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W, et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009;138:660-72.
39. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004;91:355-8.
40. Kohrmann A, Kammerer U, Kapp M, Dietl J, Anacker J. Expression ofmatrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literature. BMC Cancer 2009;9:188.
41. Merdad A, Karim S, Schulten HJ, Dallol A, Buhmeida A, Al-Thubaity F, et al. Expression ofmatrix metalloproteinases (MMPs) in primary human breast cancer:MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Res 2014;34:1355-66.
42. Newby AC. Matrix metalloproteinase inhibition therapy for vascular diseases. Vascul Pharmacol 2012;56:232-44.
43. Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelialmesenchymal transition in breast cancer. JMammary Gland BiolNeoplasia 2010;15:201-12.
44. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005; 26:513-23.
45. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010;123:725-31.
46. Labrie M, St-Pierre Y. Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci 2013;70:3109-24.
47. Chernov AV, Strongin AY. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. Biomol Concepts 2011;2: 135-47.
48. Hegedus L, Cho H, Xie X, Eliceiri GL. Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness. J Cell Physiol 2008;216:480-5.
49. Lauberth SM, Nakayama T, Wu X, Ferris AL, Tang Z, Hughes SH, et al. H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell 2013;152:1021-36.
50. Vermeulen M, Mulder KW, Denissov S, Pijnappel WW, van Schaik FM, Varier RA, et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell 2007;131:58-69.
51. Flanagan JF, Mi LZ, Chruszcz M, Cymborowski M, Clines KL, Kim Y, et al. Double chromodomains cooperate to recognize the methylated histone H3 tail. Nature 2005;438:1181-5.
52. Tam WL, Weinberg RA. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med 2013;19:1438-49.
53. Enroth S, Rada-Iglesisas A, Andersson R, Wallerman O, Wanders A, Pahlman L, et al. Cancer associated epigenetic transitions identified by genomewide histone methylation binding profiles in human colorectal cancer samples and paired normal mucosa. BMC Cancer 2011;11:450.
54. Yang H, Salz T, Zajac-Kaye M, Liao D, Huang S, Qiu Y. Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators. FASEB J 2014;28:4265-79.
55. Hallson G, Hollebakken RE, Li T, Syrzycka M, Kim I, Cotsworth S, et al. dSet1 is the main H3K4 di- and tri-methyltransferase throughout Drosophila development. Genetics 2012;190:91-100.
56. Hu D, Gao X, Morgan MA, Herz HM, Smith ER, Shilatifard A. The MLL3/ MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers. Mol Cell Biol 2013;33:4745-54.
57. Ardehali MB, Mei A, Zobeck KL, Caron M, Lis JT, Kusch T. Drosophila Set1 is the major histone H3 lysine 4 trimethyltransferase with role in transcription. EMBO J 2011;30:2817-28.
58. Herz HM, Mohan M, Garruss AS, Liang K, Takahashi YH, Mickey K, et al. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Dev 2012;26: 2604-20.
59. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, et al. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 2012;31:753-61.
60. Yang F, Sun L, Li Q, Han X, Lei L, Zhang H, et al. SET8 promotes epithelialmesenchymal transition and confers TWIST dual transcriptional activities. EMBO J 2012;31:110-23.
61. Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C, et al. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation and metastasis. Tumour Biol 2014;35:6073-82.
62. Li H, Cai Q, Godwin AK, Zhang R. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res 2010;8:1610-8.
63. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007;26: 5420-32.
64. Rabello Ddo A, de Moura CA, de Andrade RV, Motoyama AB, Silva FP. Altered expression ofMLL methyltransferase family genes in breast cancer. Int J Oncol 2013;43:653-60.